# Jean-Michel Petit

> Jean-Michel Petit is a seed investor at IRDI (Toulouse) backing Biotechnology and Therapeutics. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [IRDI](https://shizune.co/investors/profile/irdi-midi-pyrenees)
- Location: Toulouse, France
- Total investments: 10
- Last investment: Jul 2024
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jmptoulouse/?originalSubdomain=fr

Jean-Michel Petit is a seed investor at IRDI in Toulouse focused on Biotechnology and Therapeutics. Jean-Michel Petit joined IRDI SORIDEC Gestion as Investment Director in 2003.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 30% |
| Therapeutics | 2 | 20% |
| Medical | 1 | 10% |
| Chemical | 1 | 10% |
| Agriculture | 1 | 10% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 20% |
| Funding Round | 2 | 20% |
| Private Equity | 2 | 20% |
| Series A | 1 | 10% |
| Series B | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Micropep Technologies | Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control. | $29.3M | Series B | Jul 25, 2024 |  |
| Dionymer | Dionymer is putting money into the circular economy by creating a method that uses microorganisms to convert industrial organic waste into biodegradable polyhydroxyalkanoates, or PHA, polymers. | $1.6M | Seed | Dec 05, 2023 |  |
| Micropep Technologies | Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control. | $9.3M | Series A | Jun 27, 2022 |  |
| Micropep Technologies | Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control. | $10.1M | Series A | Jul 08, 2021 |  |
| SmartCatch | SmartCatch brings value-added liquid biopsy technology to empower clinicians, researchers, and industry in the fight against cancer. | $3.5M |  | May 17, 2021 |  |
| SmartCatch | SmartCatch brings value-added liquid biopsy technology to empower clinicians, researchers, and industry in the fight against cancer. | $3.9M | Seed | May 17, 2021 |  |
| Advicenne | Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $17.6M |  | Mar 20, 2017 |  |
| Advicenne Pharma SA | Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare renal diseases. | $17.6M | Private Equity | Mar 20, 2017 |  |
| Advicenne | Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $18.2M | Private Equity | Mar 20, 2017 |  |
| Advicenne | Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $18.2M | Private Equity | Mar 20, 2017 |  |

10 of 10 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 4 deals together
- [IXO Private Equity](https://shizune.co/investors/profile/ixo-private-equity) — VC Fund, 4 deals together
- [Cemag Invest](https://shizune.co/investors/profile/cemag-invest) — VC Fund, 3 deals together
- [Fall Line Capital](https://shizune.co/investors/profile/fall-line-capital) — VC Fund, 3 deals together
- [FMC Ventures](https://shizune.co/investors/profile/fmc-ventures) — VC Fund, 3 deals together
- [InnoBio](https://shizune.co/investors/profile/innobio) — VC Fund, 3 deals together

## About IRDI

VC Fund · Toulouse, France

IRDI Gestion aims to participate in the economic growth and job creation in their regions. For this, their teams create a real partnership with the companies they accompany, based on a relationship of trust and proximity.IRDI Gestion currently manages €150 million and has financial tools able to accompany the Southwest SMEs in the creationphase, development or transmission, with intervention tickets from equity € 100000 to € 5000000.Precursor of regional investment capital of the Southwest, with a presence of over 35 years, the IRDI Group consists of 3 SCR:- IRDI, created in 1981 to foster industrial growth companies based in the South West of France- MPcroissance, created in 1996 to assist small businesses in Midi-Pyrénées- IRDInov, created in 2012 under the leadership of the National Seed Fund (under the PIA) to fund the initiation of innovative companiesIn 2015, the management company IRDI Gestion, approved by the AMF, was formed to structure the group and bring new development projects.

5 contacts available at IRDI.

| Name | Title | Profile |
| --- | --- | --- |
| Alain Fabre | Director | https://shizune.co/investors/profile/alain-fabre |
| Dorothée Watine | Investment Manager | https://shizune.co/investors/profile/dorothe-watine |
| Jean-Bernard Saucède | Director of Equity | https://shizune.co/investors/profile/jean-bernard-saucde |
| Jean-Michel Petit | Investment Director | https://shizune.co/investors/profile/jean-michel-petit |
| Marc Bres Pintat | Team Member | https://shizune.co/investors/profile/marc-bres-pintat |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Jean-Michel Petit invest in?

Jean-Michel Petit invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Seed and Funding Round stage. Most of the 10 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jean-Michel Petit last invest?

The most recent investment recorded for Jean-Michel Petit closed in Jul 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co